Xofluza, also known as baloxavir marboxil, was approved by the U.S. Food and Drug Administration (FDA) in October 2018 for the treatment of acute uncomplicated influenza [1]. It is a first-in-class medication that inhibits the cap-dependent endonuclease of the influenza virus [1][2].
What is Xofluza used for?
Xofluza is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have had flu symptoms for no more than 48 hours [1]. It is also approved for the preventive treatment of influenza in patients 12 years of age and older following close contact with an individual with influenza [3].
How does Xofluza work?
Unlike older influenza medications that target viral neuraminidase, Xofluza works by inhibiting the activity of the influenza virus PA polymerase [2]. This enzyme is essential for viral replication, and its inhibition by Xofluza prevents the virus from making copies of itself [1][2].
When does Xofluza patent protection end?
Patent information for Xofluza is complex and can be tracked on sites like DrugPatentWatch.com. Generally, patent exclusivities for branded drugs vary, and details about specific patent expiry dates for Xofluza would require consulting specialized patent databases [4].
How does Xofluza compare to other flu treatments?
Xofluza's mechanism of action is distinct from neuraminidase inhibitors like oseltamivir (Tamiflu) and zanamivir (Relenza) [2]. Clinical studies have shown Xofluza to be effective in shortening the duration of flu symptoms [1]. One significant difference is that Xofluza is a single oral dose, whereas many other flu antivirals require multiple doses over several days [1][3].
Who manufactures Xofluza?
Xofluza is manufactured by Shionogi Inc. in the United States [1].
What are the potential side effects of Xofluza?
Common side effects reported in clinical trials include diarrhea, bronchitis, nausea, and headache [1]. In rare cases, individuals have experienced more severe reactions, including allergic reactions and the potential for worsening of underlying medical conditions [1].
Can drug-resistant flu strains emerge from Xofluza use?
As with any antiviral medication, there is a possibility of developing drug-resistant strains of influenza. In clinical trials, resistance mutations in the PA gene were observed, and concerns exist about the potential for increased transmission of resistant strains [1][5].
What is the dosage and administration of Xofluza?
For treatment of uncomplicated influenza, the recommended dosage is 40 mg for individuals weighing at least 80 kg and 20 mg for individuals weighing less than 80 kg, taken as a single oral dose [1]. For post-exposure prophylaxis, the dosage is also 20 mg or 40 mg, depending on weight, as a single oral dose [3].
Where can I find more information about Xofluza patents?
Detailed information regarding Xofluza's patent status, including expiry dates and any legal challenges, can be found on specialized pharmaceutical patent tracking websites such as DrugPatentWatch.com [4].
---
Sources
1. https://www.drugpatentwatch.com/
2. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-influenza-seasonal-flu
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210438lbl.pdf
4. https://www.shionogi.com/
5. https://www.cdc.gov/flu/treatment/what-to-expect.htm